[go: up one dir, main page]

IL184620A0 - Composition for the treatment of inflammation - Google Patents

Composition for the treatment of inflammation

Info

Publication number
IL184620A0
IL184620A0 IL184620A IL18462007A IL184620A0 IL 184620 A0 IL184620 A0 IL 184620A0 IL 184620 A IL184620 A IL 184620A IL 18462007 A IL18462007 A IL 18462007A IL 184620 A0 IL184620 A0 IL 184620A0
Authority
IL
Israel
Prior art keywords
inflammation
treatment
composition
Prior art date
Application number
IL184620A
Original Assignee
Can Fite Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Can Fite Biopharma Ltd filed Critical Can Fite Biopharma Ltd
Priority to IL184620A priority Critical patent/IL184620A0/en
Publication of IL184620A0 publication Critical patent/IL184620A0/en
Priority to PCT/IL2008/000976 priority patent/WO2009010967A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4875Compounds of unknown constitution, e.g. material from plants or animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL184620A 2007-07-15 2007-07-15 Composition for the treatment of inflammation IL184620A0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IL184620A IL184620A0 (en) 2007-07-15 2007-07-15 Composition for the treatment of inflammation
PCT/IL2008/000976 WO2009010967A1 (en) 2007-07-15 2008-07-15 An agent for treatment of inflammation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL184620A IL184620A0 (en) 2007-07-15 2007-07-15 Composition for the treatment of inflammation

Publications (1)

Publication Number Publication Date
IL184620A0 true IL184620A0 (en) 2008-01-20

Family

ID=39941836

Family Applications (1)

Application Number Title Priority Date Filing Date
IL184620A IL184620A0 (en) 2007-07-15 2007-07-15 Composition for the treatment of inflammation

Country Status (2)

Country Link
IL (1) IL184620A0 (en)
WO (1) WO2009010967A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL200753A (en) * 2009-09-06 2015-06-30 Can Fite Biopharma Ltd Pharmaceutical composition comprising ib-meca for the treatment of psoriasis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3620674A1 (en) * 1986-06-20 1987-12-23 Nattermann A & Cie Ointment for the treatment of skin diseases
GB8630273D0 (en) * 1986-12-18 1987-01-28 Til Medical Ltd Pharmaceutical delivery systems
US5583153A (en) * 1994-10-06 1996-12-10 Regents Of The University Of California Use of taxol in the treatment of rheumatoid arthritis
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
JP2007501864A (en) * 2003-06-11 2007-02-01 ノバセア インコーポレイティッド Treatment of immune mediated diseases by active vitamin D compounds alone or in combination with other therapeutic agents
US20080300213A1 (en) * 2005-11-30 2008-12-04 Pnina Fishman Use of A3 Adenosine Receptor Agonist in Osteoarthritis Treatment
CA2622975C (en) * 2006-01-27 2011-05-03 Can-Fite Biopharma Ltd. Adenosine a3 receptor agonists for the treatment of dry eye disorders

Also Published As

Publication number Publication date
WO2009010967A1 (en) 2009-01-22

Similar Documents

Publication Publication Date Title
HK1256861A1 (en) Compositions for the treatment of gastrointestinal inflammation
HRP20190059T1 (en) Compositions for the treatment of pain and/or inflammation
ZA201001304B (en) Compositions for the treatment of neoplastic diseases
PL1975226T3 (en) Liquid treatment composition
ZA200902374B (en) Compositions useful for the treatment of diabetes
GB0802403D0 (en) Compositions for the treatment of oxidative stress
HK1166305A1 (en) Compositions and methods for the treatment of inflammation
ZA201100653B (en) Topical composition for the treatment of ctinic keratosis
IL209360A (en) Pharmaceutical compositions comprising pm00104 for the treatment of multiple myeloma
IL205137A0 (en) 5-cyanothienopyridines for the treatment of tumours
PL2209458T3 (en) Skin treatment compositions
GB0909297D0 (en) Composition for the treatment of skin conditions
GB0715790D0 (en) Drug combination for the treatment of sialorrhoea
EP2174956A4 (en) Compositions for anti-fibrinolitic treatment
IL208624A0 (en) Compositions for the treatment of lice
PL2323625T3 (en) New composition for the treatment of ecchymotic pigmentations
GB0723100D0 (en) Treatment of HFnEF
PL2252302T3 (en) Composition for the treatment of osteoarthritis
IL184620A0 (en) Composition for the treatment of inflammation
GB0808326D0 (en) Compositions and methods for the treatment of fybromyalgia
GB0602857D0 (en) The treatment of sialorrhoea
GB0609789D0 (en) Treatment of inflammation
GB0705674D0 (en) Composition for the treatment of halitosis
GB0809319D0 (en) The treatment of puritus
GB0700572D0 (en) Composition for treating dermatological conditions